H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on NMRA stock, giving a Buy rating on January 29.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Douglas Tsao has given his Buy rating due to a combination of factors, primarily the strengthening clinical profile of NMRA-511 in Alzheimer’s-related agitation. Newly released data on global severity and agitation/aggression scales in anxious patients indicate meaningful symptom improvement, with effect sizes that suggest the drug could become a leading, non-sedating option in a large outpatient market segment.
Additional efficacy signals across multiple agitation measures appear at least comparable to, and in some respects better than, existing therapies like Rexulti, while NMRA-511’s cleaner safety profile may support higher dosing and better tolerability. On the financial side, Tsao’s $18 target price is anchored in a discounted 2035 revenue forecast focused on later-stage assets, leaving room for upside from earlier programs, though he flags regulatory, commercial, financing, and dilution risks as key constraints investors should monitor.
In another report released on January 29, Guggenheim also maintained a Buy rating on the stock with a $14.00 price target.